Pharmaceutical Business review is using cookies

ContinueLearn More
November 19, 2018

AstraZeneca’s Imfinzi fails to improve OS in Mystic lung cancer trial

AstraZeneca’s Imfinzi (durvalumab) monotherapy and the combination of Imfinzi with remelimumab have failed to improve overall survival (OS) rate in phase III Mystic lung cancer trial.

Image: AstraZeneca’s Imfinzi has failed to improve OS in lung cancer trial. Photo: courtesy of AstraZeneca.